AU666914B2 - Cytokines with an unpaired cysteine residue and conjugates thereof - Google Patents

Cytokines with an unpaired cysteine residue and conjugates thereof

Info

Publication number
AU666914B2
AU666914B2 AU33235/93A AU3323593A AU666914B2 AU 666914 B2 AU666914 B2 AU 666914B2 AU 33235/93 A AU33235/93 A AU 33235/93A AU 3323593 A AU3323593 A AU 3323593A AU 666914 B2 AU666914 B2 AU 666914B2
Authority
AU
Australia
Prior art keywords
cytokine
conjugated
cytokines
cysteine residue
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33235/93A
Other languages
English (en)
Other versions
AU3323593A (en
Inventor
Tse Wen Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU3323593A publication Critical patent/AU3323593A/en
Application granted granted Critical
Publication of AU666914B2 publication Critical patent/AU666914B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU33235/93A 1991-12-10 1992-12-10 Cytokines with an unpaired cysteine residue and conjugates thereof Ceased AU666914B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80545291A 1991-12-10 1991-12-10
US805452 1991-12-10
PCT/US1992/010889 WO1993012142A1 (fr) 1991-12-10 1992-12-10 Cytokines dotees d'un residu de cysteine non apparie et leurs produits de conjugaison

Publications (2)

Publication Number Publication Date
AU3323593A AU3323593A (en) 1993-07-19
AU666914B2 true AU666914B2 (en) 1996-02-29

Family

ID=25191607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33235/93A Ceased AU666914B2 (en) 1991-12-10 1992-12-10 Cytokines with an unpaired cysteine residue and conjugates thereof

Country Status (5)

Country Link
EP (1) EP0618927A4 (fr)
JP (1) JP2704214B2 (fr)
AU (1) AU666914B2 (fr)
CA (1) CA2124672A1 (fr)
WO (1) WO1993012142A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165458A (en) * 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
US6475796B1 (en) 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
AU5026100A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor dimers
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533209B1 (fr) * 1982-09-22 1985-11-08 Centre Nat Rech Scient Lipopeptides, leur obtention et leur application comme emulsifiants
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5082967A (en) * 1988-06-16 1992-01-21 Washington University Novel fatty acid analog enzyme substrates
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1991012229A1 (fr) * 1990-02-12 1991-08-22 National Research Council Of Canada Procede de preparation de derives acyles de composes acylables
DE69128944T2 (de) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten

Also Published As

Publication number Publication date
JP2704214B2 (ja) 1998-01-26
EP0618927A1 (fr) 1994-10-12
JPH07502508A (ja) 1995-03-16
CA2124672A1 (fr) 1993-06-24
AU3323593A (en) 1993-07-19
WO1993012142A1 (fr) 1993-06-24
EP0618927A4 (fr) 1995-05-24

Similar Documents

Publication Publication Date Title
EP1090645B1 (fr) Administration orale de protéines modifiées chimiquement
CA2325341C (fr) Molecules chimeres mutagenisees a base d'il-13
CN1072505C (zh) 生物应答修饰因子的新颖抗体传递系统
US7074755B2 (en) Erythropoietin conjugate compounds with extended half-lives
TWI406672B (zh) 生物效力增進的β干擾素聚合物共軛體
US20070219118A1 (en) Therapeutic methods for nucleic acid delivery vehicles
EP0442724A2 (fr) IL-6 humaine modifiée
ES2255713T3 (es) Factor neurotrofico que se deriva de lineas celulares truncadas gliales.
US20050176627A1 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
MXPA01003790A (es) Proteinas de fusion beta - interferon y sus usos.
WO2005025606A1 (fr) Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
JPH0725689B2 (ja) 顆粒球コロニ−刺激因子を含有する徐放性製剤
EA000415B1 (ru) Стабильные белково-фосфолипидные составы и способы их получения
JP2008509889A (ja) ペグ化インターフェロンα−１ｂ
JP2002502825A (ja) 経口運搬用共重合体組成物
JP2011132248A (ja) インターフェロンβを用いる慢性炎症性脱髄性多発性ニューロパシーの治療
AU666914B2 (en) Cytokines with an unpaired cysteine residue and conjugates thereof
US20130295052A1 (en) Novel conjugates for targeted drug delivery
KR20050083682A (ko) 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는 장기 작용성 에리트로포이에틴
TW201138831A (en) Modified granulocyte colony stimulating factor (G-CSF)
CN102584979B (zh) PEG化干扰素λ
WO1999065529A1 (fr) Complexes de cobalamine et d'acide nucleique et leur utilisation en therapie genique
JPH06501702A (ja) 腫瘍壊死因子のリポソーム処方物の製造及び特性化
CN101172160A (zh) 干扰素γ偶联物
KR20060132803A (ko) 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는장기 작용성 에리트로포이에틴

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired